AARTIDRUGS · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 38/100 — Quality 42 · Valuation 53 · Momentum 6
| Share price | ₹418.00 |
| Market cap | ₹3,622 Cr |
| P/E ratio | 18.6 |
| P/B ratio | 2.3 |
| ROCE | 12.9% |
| Dividend yield | 0.51% |
| Book value | ₹169.79 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹2,565 Cr | ₹195 Cr | 12.0% |
| 2025 | ₹2,387 Cr | ₹168 Cr | 12.0% |
| 2024 | ₹2,529 Cr | ₹172 Cr | 13.0% |
| 2023 | ₹2,716 Cr | ₹166 Cr | 11.0% |
| 2022 | ₹2,489 Cr | ₹205 Cr | 13.0% |
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL